Climb Bio, Inc.(CLYM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CLYM Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Climb Bio, Inc. (CLYM), a Healthcare sector company. CLYM is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of CLYM by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., FMR, UBS Group AG, based on the most recent SEC filings. CLYM trades on the Nasdaq exchange and files with the SEC under CIK 1768446. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLYM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Climb Bio, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-13.5M
ROIC
Q2 2026
-25.7%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+19.0% YoYOperating Income
+17.2% YoYEPS (Diluted)
+42.5% YoYTotal Assets
-22.8% YoYOp. Cash Flow
-249.3% YoYFree Cash Flow
-250.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-59.9M +19.0% | $-73.9M -110.4% | $-35.1M +22.4% | $-45.2M +4.7% | $-47.5M -129.7% | $-20.7M |
| Operating Income | $-67.9M +17.2% | $-82.0M -103.6% | $-40.3M +10.8% | $-45.1M -26.5% | $-35.7M -70.5% | $-20.9M |
| EPS (Diluted) | $-0.88 +42.5% | $-1.53 -17.7% | $-1.30 +24.4% | $-1.72 +59.4% | $-4.24 | — |
| Total Assets | $167.7M -22.8% | $217.2M +96.6% | $110.5M -18.2% | $135.0M -22.1% | $173.2M +603.3% | $24.6M |
| Operating Cash Flow | $-54.4M -249.3% | $-15.6M +24.5% | $-20.6M +44.9% | $-37.4M -3.6% | $-36.1M -155.9% | $-14.1M |
| Free Cash Flow | $-54.5M -250.5% | $-15.6M +24.5% | $-20.6M | — | — | — |
Get alerted when CLYM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Climb Bio, Inc. including:
Top Institutional Holders of CLYM
RA CAPITAL MANAGEMENT, L.P.
$147.4M11,300,939 shFMR LLC
$88.5M6,790,364 shUBS Group AG
$44.4M3,404,866 shBRAIDWELL LP
$36.5M2,797,375 shADAGE CAPITAL PARTNERS GP, L.L.C.
$32.7M2,506,000 shBlackRock, Inc.
$30.7M2,354,872 shPRICE T ROWE ASSOCIATES INC /MD/
$27.7M2,127,281 shCormorant Asset Management, LP
$27.5M2,106,000 shFRONTIER CAPITAL MANAGEMENT CO LLC
$25.3M1,939,019 shVANGUARD CAPITAL MANAGEMENT LLC
$22.2M1,698,654 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $147.4M | 11,300,939 |
| FMR LLC | $88.5M | 6,790,364 |
| UBS Group AG | $44.4M | 3,404,866 |
| BRAIDWELL LP | $36.5M | 2,797,375 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $32.7M | 2,506,000 |
| BlackRock, Inc. | $30.7M | 2,354,872 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $27.7M | 2,127,281 |
| Cormorant Asset Management, LP | $27.5M | 2,106,000 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $25.3M | 1,939,019 |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.2M | 1,698,654 |
More Healthcare Companies
View all Healthcare →Put CLYM on your watchlist
Track score changes the day Climb Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CLYM a good stock to buy?
13F Pro's AI-powered analysis of Climb Bio, Inc. (CLYM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLYM are available on the CLYM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CLYM is classified as a small company.
Which hedge funds own CLYM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLYM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Climb Bio, Inc.'s investment landscape.